Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials Cancers with homologous recombination deficiency (HRD) can ...
The Association for Molecular Pathology announced the publication of best practice recommendations for clinical laboratories developing and performing homologous recombination deficiency (HRD) testing ...
The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate ...
In the phase 3 SUBITO trial, researchers aimed to compare outcomes with intensified alkylating chemotherapy to those with an HRD-targeting regimen.
“A key objective of research focused on early-stage breast cancer is to identify biomarkers that can select patients who might benefit from less aggressive treatments than chemotherapy and personalize ...
A study led by Dr. Jason Pitt, Principal Investigator at the Cancer Science Institute of Singapore (CSI Singapore), has identified eight new "signatures" of DNA patterns (gains and/or losses) in ...
Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results